Background: There is no standard treatment after progression on second-line chemotherapy for metastatic breast cancer (MBC). We compared vinflunine with physician's choice of alkylating agent (AA) for patients with heavily pretreated MBC.
Introduction
Chemotherapy is the backbone of therapy for patients with metastatic breast cancer (MBC) previously treated with or ineligible for endocrine therapy. The aim is to gain maximal tumour control with minimal toxicity and impact on quality of life (QoL). Numerous chemotherapy regimens are available and, particularly in heavily pretreated disease, there is no standard therapy [1] . In the first-line setting, taxane-or anthracycline-based regimens are recommended if not already used as (neo)adjuvant therapy [2] . At the time, this study was initiated, commonly used agents after anthracycline/taxane therapy included capecitabine, gemcitabine, vinorelbine and ixabepilone. Ultimately, however, the majority of patients either do not respond or develop resistance to these treatments. For heavily pretreated patients, there remains a critical need for new agents with a better benefit/risk ratio.
Vinflunine, a vinca alkaloid derivative that acts as a microtubule inhibitor, is an approved monotherapy for patients with advanced/metastatic transitional cell carcinoma of the urothelial tract after failure of prior platinum-based chemotherapy and with performance status 1 [3] . The registered dose is 320 mg/m 2 /day, or 280 mg/m 2 /day in patients with a performance status of 1 or prior pelvic irradiation. In MBC, two phase II studies demonstrated promising single-agent activity for vinflunine in patients with anthracycline-and/or taxane-pretreated disease [4, 5] . Based on this encouraging activity, particularly in taxane-resistant and heavily pretreated MBC, we initiated a phase III trial comparing vinflunine with an alkylating agent (AA) of the physician's choice as third-or later-line chemotherapy for locally recurrent or metastatic breast cancer (LR/MBC).
Patients and methods

Study design
L00070 IN 308 B0 (ClinicalTrials.gov NCT01091168) was an open-label two-arm multicentre randomised phase III trial conducted in 130 centres across 20 countries. The primary objective was to demonstrate superior overall survival (OS) with vinflunine compared with the physician's choice of AA as third-or subsequent-line therapy for heavily pretreated MBC.
Patients
Key inclusion criteria were: female aged 18-75 years; histologically or cytologically confirmed measurable or non-measurable breast cancer not amenable to curative surgery or radiotherapy; at least two prior chemotherapy regimens for locally recurrent/metastatic disease; prior treatment with an anthracycline, a taxane, an antimetabolite and a vinca alkaloid (not vinflunine); no longer a candidate for any of the above chemotherapy agents because of resistance and/or intolerance (or because of a cumulative anthracycline dose 180 mg/m 2 doxorubicin or 300 mg/m 2 epirubicin); World Health Organization (WHO) performance status 2; and adequate haematological, hepatic and renal function. Prior HER2-directed therapy was permitted in patients with HER2-positive disease if discontinued 3 weeks before randomisation. Exclusion criteria included: pulmonary lymphangitis, grade 2 symptomatic pleural effusion resulting in pulmonary dysfunction that required active treatment, or grade 2 symptomatic ascites requiring paracentesis; untreated or unstable central nervous system metastases; pre-existing grade 1 motor or sensory peripheral neuropathy; vinca alkaloid treatment within 4 months before randomisation; or participation in a previous trial of vinflunine. Initially, patients who had received >5 prior chemotherapy regimens were ineligible, but this limit was removed in a protocol amendment (15 December 2009). All patients provided written informed consent before completing any study-related procedure. The protocol and study-related documents were approved by independent ethics committees and regulatory authorities in participating countries. The study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practice and local ethical and legal requirements.
Treatment
Patients were randomly assigned (1 : 1) using a central interactive voiceresponse system to either intravenous (i.v.) vinflunine 280 mg/m 2 /day on day 1 of each 3-week cycle (q3w) or the investigator's choice of AA monotherapy (oral or i.v. cyclophosphamide, oral or i.v. melphalan, mitomycin C, thiotepa, cisplatin or carboplatin) administered q3w according to the approved indication or accepted local practice. Patients received study treatment until disease progression, unacceptable toxicity or the patient's or investigator's request to discontinue. Prophylactic measures in the vinflunine arm included antiemetics before each infusion and laxatives on days 1-5 of each cycle, together with dietary measures. Use of colony-stimulating factors and erythropoietin was allowed.
Randomisation was stratified according to a minimisation procedure using the following factors: WHO performance status (0 versus 1 versus 2); number of prior chemotherapy lines for LR/MBC (initially 2/3 versus >3, modified to 2/3 versus 4/5 versus >5 after the protocol amendment of 15 December 2009), measurable disease (yes versus no) and study site.
Study end points
The primary end point was OS, defined as the interval between randomisation and date of death from any cause (or the last date the patient was known to be alive if the date of death was unknown). Secondary end points were progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1), objective response rate (ORR), disease control rate (DCR; defined as complete or partial response or stable disease), duration of response, duration of disease control, time to response in patients with complete or partial response, safety and health-related QoL (assessed using European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire core module [QLQ-C30] and breast cancer-specific module [QLQ-BR23]). Tumour response was determined according to RECIST (version 1.1) every two cycles (or earlier if progression was suspected). Adverse events (AEs) were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). QLQ-C30 and QLQ-BR23 were completed by patients before randomisation, every 6 weeks during treatment and at treatment discontinuation.
Statistical analysis
The planned sample size was at least 586 patients, which provided 80% power with a two-sided a of 0.05 to detect an increase in median OS from 6.5 months in the control arm to 8.5 months in the vinflunine arm [hazard ratio (HR) 0.765] after 437 deaths. OS was compared between treatment arms using a log-rank test at a 5% significance level, stratified using all randomisation stratification factors except study site. HRs and corresponding 95% confidence intervals (CIs) were calculated using a Cox proportional hazards model. Time-related end points were analysed using Kaplan-Meier methodology. Efficacy was analysed in the intent-to-treat (ITT) population comprising all randomised patients. Safety was analysed in all patients who received at least one dose of study treatment. Patient-reported outcomes were analysed in the evaluable population for each questionnaire, scored according to EORTC recommendations. The primary QoL parameter was global health status (QLQ-C30).
Results
Patients
Between 15 July 2009 and 11 October 2011, 594 patients were randomised: 298 to vinflunine and 296 to AA (Figure 1 ). Baseline patient demographics and disease characteristics were generally well balanced (Table 1) . The majority of patients in both treatment arms had developed resistance to anthracycline, taxane, antimetabolite and vinca alkaloid therapies, and most had received the maximum cumulative dose of anthracycline therapy. In addition, approximately one-quarter had received prior bevacizumab. Approximately one-fifth of the patients had triplenegative disease and one-fifth had HER2-positive disease.
Treatment exposure
Most patients (71%) in the AA arm received i.v. therapy (32% carboplatin, 16% cisplatin, 15% mitomycin C, 6% cyclophosphamide, 2% melphalan and 1% thiotepa). In the remaining 29% of patients, the physician selected an oral AA (28% cyclophosphamide, 1% melphalan). In both treatment arms, patients received a median of three cycles of study therapy (range 1-28 in the vinflunine arm, 1-30 in the AA arm). The median relative dose intensity of vinflunine was 98.6% (range 67.8%-110.7%). Treatment was delayed by >3 days in 34% of vinflunine-treated patients (16% of cycles excluding cycle 1) and 36% of AA-treated patients (21% of cycles excluding cycle 1). In both treatment arms, the major cause of dose delay was treatment-related haematological toxicity (13% in the vinflunine arm, predominantly neutropenia; 22% in the AA arm, predominantly neutropenia and thrombocytopenia). Dose reductions were implemented in 13% of vinflunine-treated patients and 10% of AA-treated patients. At the time of data cut-off, three patients in the vinflunine arm (and none in the AA arm) remained on study treatment.
After disease progression, most patients in both treatment arms received additional therapy (77% in the vinflunine arm and 77% in the AA arm), typically with further chemotherapy (64% versus 65%, respectively).
Efficacy
At the data cut-off date (27 August 2012), 472 patients had died. The HR for OS was 1.04 (95% CI 0.86-1.25, P ¼ 0.67), indicating no difference between treatment arms (Figure 2A ). Median OS was 9.1 months (95% CI 7.7-10.4 months) with vinflunine and 9.3 months (95% CI 7.5-10.9 months) with AA. The HR for PFS was 0.94 (95% CI, 0.80-1.12; P ¼ 0.49) ( Figure 2B ). Median PFS was 2.5 months (95% CI 1.7-2.7) with vinflunine versus 1.9 months (95% CI 1.5-2.6 months) with AA. The ORR was similar in the two study arms (6% with vinflunine versus 4% with AA; Table 2 ). However, the DCR was significantly higher with vinflunine versus AA (44% versus 35%, respectively; P ¼ 0.04) and time to first response was numerically shorter with vinflunine. Additional secondary efficacy end points are summarised in Table 2 .
Subgroup analyses of OS generally demonstrated consistency with results in the ITT population (Supplementary Figure S1 , available at Annals of Oncology online). 
Quality of life
QLQ-C30 questionnaires were assessable in 208 patients (70%) in the vinflunine arm and 138 (47%) in the AA arm at baseline. Corresponding figures for QLQ-BR23 were 199 (67%) and 125 (42%), respectively. At week 6, the compliance rate for QLQ-C30 was 57% versus 20% in the vinflunine and AA arms, respectively, and by week 12, compliance had decreased to 26% and 6%. Global health status decreased at all evaluations after baseline in both treatment arms, with a more pronounced decrease in the AA than the vinflunine arm.
Safety
AEs are summarised in Table 3 . The most common AEs with vinflunine were gastrointestinal disorders (constipation, nausea, g Defined as lung, liver, pleural, malignant pleural effusion, heart (pericardium), peritoneum (malignant ascites), spleen or adrenal glands. AA, alkylating agent; NOS, not otherwise specified; WHO, World Health Organization.
abdominal pain, stomatitis), haematological toxicities and asthenia. The most common AEs with AA were haematological toxicities, nausea and asthenia. Most AEs in both treatment arms were grade 1/2. Grade 3/4 AEs were reported in 48% of vinfluninetreated patients (most commonly neutropenia and asthenia) and 38% of AA-treated patients (most commonly neutropenia and thrombocytopenia). The incidences of anaemia and neutropenia were similar in the two treatment arms, but thrombocytopenia was more common with AA. In the vinflunine arm, febrile neutropenia was reported in two patients (1%) and neutropenic infection in seven patients (2%). In the AA arm, febrile neutropaenia and neutropenic infection each occurred in only one patient (0.3%). Constipation, abdominal pain, stomatitis, asthenia, myalgia and injection-site reaction were more common with vinflunine than AA. However, complications such as intestinal obstruction (1%) and ileus (2%) were rare with vinflunine.
There were six fatal AEs (within 30 days after the last study drug administration), none of which was considered related to study drug: four patients (1.3%) in the vinflunine arm (one case each of haematemesis, pulmonary embolism, upper gastrointestinal haemorrhage and acute respiratory failure) and two (0.7%) in the AA arm (one case each of lobar pneumonia and cardiac failure). Serious AEs (SAEs) were slightly more frequent with vinflunine than AA (28% versus 23%, respectively, for SAEs irrespective of relationship to study treatment; 11% versus 2%, respectively, for SAEs considered related to study therapy).
Treatment was discontinued because of AEs in 21 patients (7%) in the vinflunine arm and 24 (8%) in the AA arm. AEs led to dose reductions in 13% of patients in the vinflunine arm and 10% in the AA arm. The most frequent AEs leading to dose reductions or treatment discontinuations were non-haematological toxicities with vinflunine (typically gastrointestinal disorders) and haematological toxicities with AA (predominantly thrombocytopenia). Constipation rarely led to vinflunine treatment modification [dose reduction in three patients (1%) and treatment discontinuation in one patient (0.3%)]. Growth factors were administered in 14% of vinfluninetreated patients and laxatives in 82%.
Discussion
In this trial, the primary objective was not met as no difference in OS was observed between vinflunine 280 mg/m 2 and the physician's choice of AA in this population of patients with heavily pretreated MBC. Similarly, there was no difference between treatment arms in either PFS or ORR, although the rate of disease control was significantly higher in the vinflunine arm.
In MBC, particularly in settings with short post-progression survival, such as this heavily pretreated population undergoing treatment after failure of multiple lines of chemotherapy, OS remains the gold standard for assessing efficacy. Since the present trial was designed, results have been reported from three randomised phase III trials evaluating single-agent therapy in anthracycline-and taxane-pretreated MBC: EMBRACE, NCT00337103 and BEACON. Only one of these trials-EMBRACE-reported positive results, with eribulin demonstrating significantly superior OS, PFS and ORR compared with physician's choice of treatment in patients previously treated with a median of four chemotherapy regimens including an anthracycline and a taxane [6] . In a second phase III trial comparing eribulin with capecitabine in anthracycline-and taxane-pretreated MBC, there was no significant improvement in PFS, OS or ORR versus capecitabine alone [7] . The third trial, BEACON, evaluated etirinotecan pegol, a long-acting topoisomerase-I inhibitor, in patients pretreated with capecitabine as well as an anthracycline and a taxane. Etirinotecan pegol did not improve OS compared with physician's choice of treatment [8] . Additional phase III trials have evaluated combination regimens in anthracycline-and taxane-pretreated MBC [9] [10] [11] [12] [13] but guidelines generally recommend sequential monotherapy instead of combination regimens.
A unique feature of our trial is the inclusion of patients treated with all four of the most commonly used classes of agents: anthracyclines, taxanes, antimetabolites (including capecitabine in 85% of patients) and vinca alkaloids. Median PFS of 2.5 months and median OS of 9.1 months in the present study are shorter than findings in the phase III trials mentioned above, presumably because this was a more heavily pretreated population of patients treated in later lines. The particularly poor prognosis of the population in our trial is illustrated by the short treatment duration in both arms (median three cycles, corresponding to 9 weeks). Interestingly, a subgroup analysis of the EMBRACE trial suggested that the efficacy of eribulin was more pronounced in the third-to fourth-line settings than in later lines. It is plausible that evaluation of vinflunine (and etirinotecan pegol) in earlier treatment lines or less heavily pretreated patients may have shown an effect on clinical outcome.
The safety profile of vinflunine 280 mg/m 2 q3w was manageable and consistent with previous studies. Grade 3/4 neutropenia was rarely complicated by febrile neutropenia or neutropenic infection. Constipation, a well-known class effect of vinca alkaloids, was relatively common with vinflunine but was typically grade 1/2. Grade 3 peripheral neuropathy was reported in only 1% of patients and no grade 4 episodes were reported. This compares favourably with incidences of grade 3/4 peripheral neuropathy reported with ixabepilone/capecitabine combination therapy (23-25%), utidelone/ capecitabine combination therapy (22%), eribulin mesylate (7-8%) and nab-paclitaxel (10%) [6, 7, [9] [10] [11] 14] . The low compliance rates, particularly in the AA arm, make QoL results difficult to interpret. In summary, vinflunine at a dose of 280 mg/m 2 demonstrated median OS of 9.1 months in patients with heavily pretreated MBC and failed to demonstrate an improvement in OS, PFS or ORR compared with AA. The low response rates, short PFS and OS of 9 months emphasise the dismal prognosis for these patients and the need for better treatment options. Nevertheless, the favourable tolerability profile of vinflunine in heavily pretreated MBC may support evaluation in an earlier treatment setting using a higher dose of vinflunine (similar to that used in advanced/metastatic transitional cell carcinoma of the urothelial tract).
